Laboratory operator Quest Diagnostics beat Wall Street estimates for first-quarter profit on Tuesday, helped by robust demand for its diagnostic tests.

Evergreen Capital Management boosted its Regeneron stake by 362.9%, snatching up 3,030 more shares and flexing some serious ...

including the California State Science Fair (April 2025), the national Thermo Fisher Scientific Junior Innovators Challenge (June 2025), and the Regeneron International Science & Engineering Fair ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $831.43, with a high estimate of $1013.00 and a low estimate of $547.00. Highlighting a 8.86% ...

Analysts at Leerink agreed with Sanofi that, despite falling short of statistical significance in the Phase II TIDE-Asthma trial, amlitelimab warrants further development in this indication.

That wound up well above expectations, Leerink Partners analyst Whit Mayo said in a research note. BTIG analyst David Larsen said separately that the final increase more than doubled what was ...

That wound up well above expectations, Leerink Partners analyst Whit Mayo said in a research note. BTIG analyst David Larsen said separately that the final increase more than doubled what was ...

Leerink Partnrs analyst M. Cherny now expects that the medical research company will earn $2.58 per share for the quarter, down from their prior estimate of $2.59. Leerink Partnrs currently has a ...

A drugmaker with one of the world's top-selling drugs Regeneron (NASDAQ: REGN) is a well-established biotech company that generates consistent revenue and profits. However, the drugmaker ...